Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2025-08-18 00:00:00 ET · period of report 2025-05-15 · accession 0001415889-25-022224 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-08-18 | 2025-05-15+ | ARTV | Aslan Fred | Pres, CEO, Dir | F - Tax | $2.44 | -8,944 | 382.2K | -2% | -$21.8K |
| 2025-08-18 | 2025-08-15 | ARTV | Aslan Fred | Pres, CEO, Dir | S - Sale | $2.73 | -25.5K | 386.7K | -6% | -$69.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-15 | F | D | 4,472 | $2.13 | 412,193 | D | — | — | (F1) Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. |
| 2 | Common | Common Stock | 2025-08-15 | S | D | 25,500 | $2.73 | 386,693 | D | — | — | (F2) Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 23, 2024, to satisfy income tax obligations associated with the vesting of restricted stock unit awards. (F3) The weighted average sale price for the transaction reported was $2.7286, and the range of prices were between $2.60 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2025-08-15 | F | D | 4,472 | $2.75 | 382,221 | D | — | — | (F1) Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. |